详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

Is the beta Common Receptor the Key Molecule for the Protective Effect of Erythropoietin?

66| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Institute of Cerebrovascular Disease Research and Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China. [2]Beijing Geriatric Medical Research Center and Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases, Beijing, China. [3]Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China

出处：

DOI：

ISSN：

关键词： erythropoietin beta common receptor ischemic stroke myocardial infarction EPO heteroreceptor

摘要：

Erythropoietin is generally assumed to have protective effects against multiple diseases, especially ischemic stroke, and myocardial infarctions. The theory behind Erythropoietin's (EPO) protective effects has been misconstrued in the scientific community to a degree, with assumptions made that the beta common receptor (beta cR) in the heteroreceptor EPO receptor (EPOR)/beta cR is responsible for these protective effects. Our purpose with this opinion article is to convey our concern for the general assumption of the importance of beta cR in EPO's protective effect and to emphasize the necessity of further research in this field.

基金：

基金编号： 7222083 81971222

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 1 区

医学

小类 | 1 区老年医学

最新[2023]版：

大类 | 2 区医学

小类 | 3 区老年医学

JCR分区：

出版当年[2021]版：

Q1 GERIATRICS & GERONTOLOGY

最新[2023]版：

Q1 GERIATRICS & GERONTOLOGY

影响因子： 7 最新[2023版] 7.1 最新五年平均 9.968 出版当年[2021版] 8.615 出版当年五年平均 6.745 出版前一年[2020版] 7.4 出版后一年[2022版]

第一作者：

第一作者机构： [1]Institute of Cerebrovascular Disease Research and Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.

共同第一作者：

通讯作者：

通讯机构： [1]Institute of Cerebrovascular Disease Research and Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China. [2]Beijing Geriatric Medical Research Center and Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases, Beijing, China. [3]Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China [*1]Xuanwu Hospital of Capital Medical University, Beijing, China [*2]Beijing Geriatric Medical Research Center and Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases, Beijing, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the β-common receptor in mice with cerebral ischemic stroke [2]Erythropoietin promotes the differentiation of fetal neural stem cells into glial cells via the erythropoietin receptor-beta common receptor/Syne-1/H3K9me3 pathway [3]血清炎性标记物对急性心肌梗死患者冠状动脉介入术后无复流的预测价值 [4]Analysis of Adverse Events in Elderly Patients with Acute Myocardial Infarction Combined Ischemic Stroke History [5]The effects of erythropoietin on neurogenesis after ischemic stroke [6]Remote ischemic conditioning reduces adverse events in patients with acute ischemic stroke complicating acute myocardial infarction: a randomized controlled trial [7]Recombinant human erythropoietin increases cerebral cortical width index and neurogenesis following ischemic stroke [8]Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes) [9]Dual Antiplatelet Therapy for Minor Stroke and High-Risk Transient Ischemic Attack What Have We Learned? [10]Closure Versus Medical Therapy for Preventing Recurrent Stroke in Patients With Patent Foramen Ovale and a History of Cryptogenic Stroke or Transient Ischemic Attack